Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform

被引:104
作者
Shiwa, M
Nishimura, Y
Wakatabe, R
Fukawa, A
Arikuni, H
Ota, H
Kato, Y
Yamori, T
机构
[1] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan
[2] Ciphergen Biosyst KK, Yokohama Lab, Hodogaya Ku, Kanagawa 2400005, Japan
[3] SC Biosci KK, Yokohama Lab, Hodogaya Ku, Kanagawa 2400005, Japan
[4] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Toshima Ku, Tokyo 1708455, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Surg, Toshima Ku, Tokyo 1708455, Japan
关键词
ProteinChip; SELDI; biomarker; expression difference mapping; RC-MS; colon cancer;
D O I
10.1016/S0006-291X(03)01520-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Useful biomarkers are needed for early detection of cancers. To demonstrate the potential diagnostic usefulness of a new proteomic technology, we performed Expression Difference Mapping analysis on 39 cancer cell lines from 9 different tissues using ProteinChip technology. A protein biomarker candidate of 12kDa was found in colon cancer cells. We then optimized the purification conditions for this biomarker by utilizing Retentate Chromatography mass spectrometry (RC-MS). The optimized purification conditions developed "on-chip" were directly transferred to conventional chromatography to purify the biomarker, which was identified as prothymosin-alpha by ProteinChip time-of-flight mass spectrometry (TOF MS) and ProteinChip-Tandem MS systems, The relative expression level of prothymosin-alpha between colon cancer cells and normal colon mucosal cells was evaluated on the same ProteinChip platform. Prothymosin-alpha expression in colon cancer cells was clearly higher than in normal colon cells. These results indicate that prothymosin-alpha could be a potential biomarker for colon cancer, and that the ProteinChip platform could perform the whole process of biomarker discovery from screening to evaluation of the identified marker. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:18 / 25
页数:8
相关论文
共 39 条
  • [1] Adam BL, 2002, CANCER RES, V62, P3609
  • [2] New technologies for the identification of markers for early detection of ovarian cancer
    Bandera, CA
    Ye, B
    Mok, SC
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2003, 15 (01) : 51 - 55
  • [3] DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation
    Bane, TK
    LeBlanc, JF
    Lee, TD
    Riggs, AD
    [J]. NUCLEIC ACIDS RESEARCH, 2002, 30 (14) : e69
  • [4] SERUM MARKERS IN GERM-CELL NEOPLASMS
    BARTLETT, NL
    FREIHA, FS
    TORTI, FM
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1991, 5 (06) : 1245 - 1260
  • [5] Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer
    Carter, D
    Douglass, JF
    Cornellison, CD
    Retter, MW
    Johnson, JC
    Bennington, AA
    Fleming, TP
    Reed, SG
    Houghton, RL
    Diamond, DL
    Vedvick, TS
    [J]. BIOCHEMISTRY, 2002, 41 (21) : 6714 - 6722
  • [6] Cazares LH, 2002, CLIN CANCER RES, V8, P2541
  • [7] The ProteinChip ® Biomarker System from Ciphergen Biosystems:: a novel proteomics platform for rapid biomarker discovery and validation
    Chapman, K
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 : 82 - 87
  • [8] Dan S, 2002, CANCER RES, V62, P1139
  • [9] Davies H, 1999, BIOTECHNIQUES, V27, P1258
  • [10] DIES M, 1994, ANTICANCER RES, V14, P2819